ERBB2 and gastric cancer: Recently, the initial findings of the first interim analysis of KEYNOTE-811, a phase 3 clinical trial assessing the effectiveness of pembrolizumab or a placebo in combination with trastuzumab and chemotherapy for HER2-positive (IHC 3+ or IHC 2+ with ISH positivity) gastric cancer in the first-line setting, have been reported [71].